Navigation Links
Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
Date:9/23/2008

r and lead medical negotiator for FDA interactions for AIR(R) Insulin, Lilly's inhaled insulin program.

During its first five years of development, Dr. Muchmore was the sole physician on the Lilly inhaled insulin development effort and the AIR(R) Insulin team. He was responsible for designing and executing all of the early phase studies and he successfully advanced the program to Phase III. Dr. Muchmore's responsibilities at Lilly also included the evaluation of promising new technologies, which is how he became aware of Halozyme's proprietary insulin program and its recombinant human hyaluronidase enzyme technology. Prior to leading Lilly's inhaled insulin program, Dr. Muchmore served on the Evista Product Team for osteoporosis and breast cancer indications from 1995 to 1999 and as its Physician Group Leader from 1997 to 1999. He is the recipient of numerous awards for professional achievement, including the Eli Lilly Global Brand Development Team Leadership Award in 2007.

From 1982 to 1995, Dr. Muchmore was staff endocrinologist at the Scripps Clinic and Research Foundation, holding additional appointments as Clinical Assistant Professor of Medicine, UCSD, and Senior Physician, The Whittier Institute for Diabetes and Endocrinology. Dr. Muchmore also served as visiting endocrinologist at the Logan Heights Community Clinic in San Diego. He received his AB degree in Biological Sciences from Stanford University, his MD from UCSD, and initiated his internship and residency training in internal medicine at the University of Washington Affiliated Hospitals in Seattle, Washington. He finished his residency training in 1978 at the Martinez Veterans Hospital, affiliated with the University of California, Davis. Dr. Muchmore completed a Fellowship in Endocrinology and Metabolism, followed by Instructorship in Medicine, at University Hospital, Seattle in 1982.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
4. Halozyme Therapeutics Amends Stockholder Rights Plan
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
8. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
9. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
10. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
11. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014   Synthetic Biologics, ... of pathogen-specific therapies for serious infections and ... microbiome, today announced positive topline safety and ... trial of SYN-004, the Company,s investigational oral ... Clostridium difficile (C. difficile) infection, antibiotic-associated ...
(Date:12/22/2014)... 22, 2014 GenomeDx Biosciences today announced that ... Classifier, a genomic test for prostate cancer, was able ... managed by radical prostatectomy without adjuvant therapy. Although rapid ... uncommon, using tumor genomics to identify these men who ... an important advance. The study has been published ...
(Date:12/22/2014)... ITRA Global, one of the largest organizations ... estate, has further expanded its global reach with the ... Western Australia, reports Mylinda Vick, CCIM, Chairman of the ... / ACORPP (Australian Corporate Property and Projects) , is ... services to a wide range of clients in the ...
(Date:12/19/2014)... Charm Sciences is pleased to announce ... of Aflatoxin M1 in raw commingled milk is the ... validation. The peer reviewed report of the validation by ... Agricultural and Fisheries Research (ILVO-T&V) has been published by ... the most toxic aflatoxin and a known carcinogen, can ...
Breaking Biology Technology:Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... NEW HAVEN, Conn., March 17 VION,PHARMACEUTICALS, INC. (Nasdaq: ... quarter and year-end of 2007., The Company reported ... share,for the year ended December 31, 2007, compared with ... for 2006. Weighted-average common shares,outstanding for the years ended ...
... -Abstract describes six-gene biomarker panel for assessment of current risk ... ... 17 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN),a company focused on ... the early detection of diseases and personalized,health management, today announced ...
... March 17 Axial Biotech, Inc., a company,revolutionizing ... motion preserving technologies, announced today that it has ... the first genetic,prognostic test for Adolescent Idiopathic Scoliosis ... its Series B financing. The Series B financing ...
Cached Biology Technology:Vion Reports 2007 Fourth Quarter and Year-End Results 2Vion Reports 2007 Fourth Quarter and Year-End Results 3Vion Reports 2007 Fourth Quarter and Year-End Results 4GeneNews selected to present late-breaking abstract at AACR Annual Meeting 2Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing 2
(Date:12/5/2014)... , Dec. 4, 2014 Increased ... boosted investments in new testing and inspection technologies. ... given rise to a range of innovative test ... requirements of Generation Y, which is generally more ... a result, product development strategies of test equipment ...
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
(Date:11/18/2014)... , Nov. 18, 2014  The Secure Identity ... Association today jointly announce the formation of The ... of its Identity and Biometric Entry and ... Framework received official support from BORDERPOL, the international ... improve and provide expertise regarding border security, traveler ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... Wheat plants found to be resistant to Hessian fly ... rigid defenses. Christie Williams, a research scientist with ... a Purdue University associate professor of entomology, found that ... production of surface waxes and cutin, a molecule responsible ...
... physically weaker as they age? And is there any way ... link between increasing age and frailty? In a ... Clinical Endocrinology & Metabolism , University of Texas Medical Branch ... questions can be found in the way the network of ...
... power of synchrotron light to Minnesota,s academic and industrial ... of Agreement (MOA) signed today between the BioBusiness Alliance ... Canadian Light Source (CLS). "The goal of ... while improving operating efficiency for both Minnesota and Canadian ...
Cached Biology News:Resistant wheat rebuilds cell walls when attacked by Hessian flies 2Muscle loss in elderly linked to blood vessels' failure to dilate 2BioBusiness Alliance, Canadian Light Source Synchrotron sign agreement 2
... DNA Polymerase is a premium quality recombinant ... thermostable enzyme is suitable for a wide ... highest purity and reproducible performance, each preparation ... quality control assays. NovaTaq DNA Polymerase possesses ...
... cell sorter sets a new standard for ... a revolutionary new design in instrumentation, this ... multicolor analysis. The BD FACSAria instrument is ... fixed-alignment cuvette flow cell. This new ...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse polyclonal antibody raised against a partial recombinant IFNA13. NCBI Entrez Gene ID = 3447...
Biology Products: